[{"id":"d494a72a-9ff2-45f5-b7e1-6d9a0c5e5875","acronym":"","url":"https://clinicaltrials.gov/study/NCT05503797","created_at":"2022-08-17T14:55:09.900Z","updated_at":"2025-02-25T14:09:04.053Z","phase":"Phase 2","brief_title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","source_id_and_acronym":"NCT05503797","lead_sponsor":"Fore Biotherapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/27/2025","primary_completion_date":" 06/27/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-17"},{"id":"72272cbc-c9f7-4112-ac79-128d9c683b5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06610682","created_at":"2025-02-26T07:01:00.356Z","updated_at":"2025-02-26T07:01:00.356Z","phase":"Phase 1","brief_title":"Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib","source_id_and_acronym":"NCT06610682","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/10/2025","start_date":" 01/10/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-01-13"},{"id":"32db5143-857f-465d-8951-6f8b2a948826","acronym":"","url":"https://clinicaltrials.gov/study/NCT02428712","created_at":"2021-01-17T17:19:42.634Z","updated_at":"2024-07-02T16:35:10.830Z","phase":"Phase 1/2","brief_title":"A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors","source_id_and_acronym":"NCT02428712","lead_sponsor":"Fore Biotherapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-09"}]